Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease

The New England Journal of Medicine
H R Gralnick, M E Rick

Abstract

We gave danazol (600 mg per day orally for 14 days), an attenuated androgen, to four adults with classic hemophilia and one adult with Christmas disease. The levels of factor VIII in the patients with classic hemophilia ranged from 1 to 3 per cent before treatment and rose to 3 to 8 per cent during the treatment period. The level of factor IX in the patient with Christmas disease rose from 5 to 14 per cent. The rise in clotting-factor activity was usually observed within five to six days after the initiation of therapy and peaked between 7 and 13 days. The drug had no untoward effects. During the 70 patient-days of therapy, only two patients required plasma products, each on one occasion. These data suggest that danazol therapy may decrease the hemorrhagic tendency and reduce the need for transfusions of plasma products in classic hemophilia and Christmas disease. Controlled clinical trials will be required to establish its value in these applications.

References

May 5, 1977·The New England Journal of Medicine·H R GralnickB S Coller
Dec 23, 1976·The New England Journal of Medicine·J A GelfandM M Frank
Dec 1, 1980·Annals of Internal Medicine·S W HoseaM M Frank

❮ Previous
Next ❯

Citations

Apr 1, 1986·European Journal of Pediatrics·T SumerM I Al-Mouzan
Jan 1, 1986·Springer Seminars in Immunopathology·R G Lahita
Aug 27, 1983·Lancet·F E PrestonD S Segal
Apr 29, 1998·European Journal of Obstetrics, Gynecology, and Reproductive Biology·M GoldenbergD Bider
Sep 14, 2001·Haemophilia : the Official Journal of the World Federation of Hemophilia·S MukhopadhyayV P Choudhry
Jun 9, 1983·The New England Journal of Medicine·J A Gelfand
Jul 5, 1984·The New England Journal of Medicine·W K Krick
Aug 30, 1984·The New England Journal of Medicine·J L Wautier, J P Caen
Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S HirosawaK Kurachi
May 27, 2006·Current Opinion in Otolaryngology & Head and Neck Surgery·Murat BasGeorg Kojda
Nov 20, 2012·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Adrian E RoşcaLeon Zăgrean
Jan 1, 1988·Veterinary Clinical Pathology·M K Boudreaux, A R Dillon
Dec 10, 1983·British Medical Journal·P Jones
Feb 15, 1989·American Journal of Ophthalmology·L M HamedT H Perez
Aug 1, 1992·Journal of the American Geriatrics Society·O F BallesterL Balducci
Dec 18, 2001·Journal of Vascular Surgery·R G AlvaradoR M Zwolak
Dec 10, 2016·Chemical Biology & Drug Design·Suman Jyoti DekaVishal Trivedi
Apr 1, 1991·The Journal of Allergy and Clinical Immunology·M CicardiA Agostoni
Jan 1, 1994·Stroke; a Journal of Cerebral Circulation·A S JaillardM Mallaret
Sep 1, 1985·Pediatric Annals·G Karayalcin
May 1, 1992·The Annals of Pharmacotherapy·M L MeeksM D Katz
Jan 1, 1984·Scandinavian Journal of Haematology. Supplementum·E G Tuddenham
Sep 1, 1986·Asia-Oceania Journal of Obstetrics and Gynaecology·G NakamuraY Nagata
Nov 25, 2020·Blood Reviews·Dawn SwanJecko Thachil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.